Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | HTR7 | P34969 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089938 | 0.91 | KCNH2 (0.80) | KCNH2SIGMAR1HTR1AHTR7 | |
| SCHEMBL2094039 | 0.87 | KCNH2 (0.69) | KCNH2SIGMAR1HTR1AHTR7SLC6A4 | |
| SCHEMBL30767216 | 0.87 | KCNH2 (0.90) | KCNH2SIGMAR1HTR1AHTR7SLC6A2 | |
| SCHEMBL4525555 | 0.85 | KCNH2 (1.00) | KCNH2SIGMAR1HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL7658247 | 0.85 | KCNH2 (0.88) | KCNH2SIGMAR1HTR1AHTR7SLC6A2 | |
| SCHEMBL1254408 | 0.85 | KCNH2 (0.77) | KCNH2SIGMAR1HTR1AHTR7 | |
| SCHEMBL4255352 | 0.84 | KCNH2 (0.74) | KCNH2SIGMAR1HTR1AHTR7 | |
| SCHEMBL30764776 | 0.84 | KCNH2 (0.74) | KCNH2SIGMAR1HTR1AHTR7 | |
| SCHEMBL7289093 | 0.84 | KCNH2 (0.74) | KCNH2SIGMAR1HTR1AHTR7 | |
| SCHEMBL8467046 | 0.84 | KCNH2 (0.74) | KCNH2SIGMAR1HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1208333-C | Indole derivatives useful A.O. for the treatment of osteoporosis | NIKEM RESEARCH SRL (IT) | 2005-06-29 | — | — | CN | claimed |
| CN-1461216-A | Compounds for use as medicaments for the treatment of disorders involving bronchoconstriction | RESPIRATORIUS AB (SE) | 2003-12-10 | — | — | CN | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| CN-1208333-C | Indole derivatives useful A.O. for the treatment of osteoporosis | NIKEM RESEARCH SRL (IT) | 2005-06-29 | — | — | CN | disclosed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | disclosed |
| EP-1187813-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| CN-1299357-A | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LAB PHARMA (FR) | 2001-06-13 | — | — | CN | disclosed |
| WO-2001000587-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-04 | — | — | WO | disclosed |
| EP-1042316-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 2000-10-11 | — | — | EP | disclosed |
| CN-1241184-A | Indole derivatives for the treatment of osteoporosis | SMITHKLINE BEECHAM SPA (IT) | 2000-01-12 | — | — | CN | disclosed |
| WO-1999033822-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1999-07-08 | — | — | WO | disclosed |
| US-5767275-A | Preparation of triazolone compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1998-06-16 | — | — | US | disclosed |
| EP-0668857-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLONE COMPOUNDS | ACRAF (IT) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SOST, NR3C2, EBP | KCNH2 1696/4885SIGMAR1 85/4885HTR1A 300/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | KCNH2 3121/4885SIGMAR1 161/4885HTR1A 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.